Table 3.

Canadian organizations involved in the cancer drug review/funding process

Name	Mission/description	Role in formulary process
Canadian Cancer Society (CCS)	The CCS is a national, community‐based organization of volunteers whose mission is the eradication of cancer and the enhancement of the quality of life of people living with cancer. Read more: http://www.cancer.ca/en/about‐us/our‐mission/#ixzz49g3QIdZo	Indirect. Supporting documentation may be provided to support submissions to the pCODR process from patients or provincial advisory groups.
Canadian Association of Provincial Cancer Agencies (CAPCA)	CAPCA is an inter‐provincial organization of provincial/territorial cancer agencies/programs engaged in cancer control. CAPCA supports the reduction of the burden of cancer on Canadians and advocacy for cancer care and control. Collectively, the members of CAPCA work to reduce the burden of cancer by promoting the highest quality of care and services for all Canadians affected by cancer and at risk of cancer, and implementing the cancer control strategy in their respective provinces. http://www.capca.ca/	Specific member organizations are often the submitters of the patient perspective documents for purposes of the pCODR process.
Canadian Cancer Research Alliance (CCRA)	An alliance of organizations that collectively fund most of the cancer research conducted in Canada—research that will lead to better ways to prevent, diagnose, and treat cancer and improve survivor outcomes. Our members include federal research funding programs/agencies, provincial research agencies, provincial cancer care agencies, cancer charities, and other voluntary associations. http://www.ccra‐acrc.ca/index.php	Indirect. Member organizations may fund some clinical evidence brought to the pCODR process.
Canadian Partnership Against Cancer (CPAC)	The CPAC s an independent organization funded by the federal government to accelerate action on cancer control for all Canadians. The Partnership works with cancer experts, charitable organizations, government, cancer agencies, national health organizations, patients, survivors, and others to implement Canada's cancer control strategy. http://www.partnershipagainstcancer.ca/who‐we‐are/	Involved in some of the submissions from patient groups.
Council of Canadian Cancer Registries	The Canadian Cancer Registry is an administrative survey. Beginning with cases diagnosed in 1992, cancer incidence collected by provincial and territorial cancer registries have been reported to the Canadian Cancer Registry, which is maintained by Statistics Canada.	Indirect. Information may be used by Provincial Advisory Groups in their submissions for purposes of the pCODR process.
National Breast Cancer Research Framework	The National Breast Cancer Research Framework is the product of a broad‐based, comprehensive, and collaborative process. It reflects the input of funders, breast cancer survivors, researchers, and clinicians from across the country and, looking ahead, offers a coherent vision of the most promising areas for breast cancer research.	Indirect. May connect researchers with funding opportunities, which lead to evidence used in the pCOD process.
Pan‐Canadian Pharmaceutical Alliance (PCPA)	The PCPA was formed in 2010 under the Council of the Federation to join provinces and territories to negotiate prices for publicly covered drugs. The PCPA examines all drugs recommended for funding by the Common Drug Review and the pan‐Canadian Oncology Drug Review, then decides whether joint pan‐Canadian negotiations occur.	Post pCODR process. Price negotiations, if successful, may lead to a re‐assessment of a drug by pCODR.
Patented Medicine Prices Review Board	The PMPRB is an independent quasi‐judicial body established by Parliament in 1987 under the Patent Act. The PMPRB protects the interests of Canadian consumers by ensuring that the prices of patented medicines sold in Canada are not excessive. It does this by reviewing the prices that patentees charge for each individual patented drug product in Canadian markets. http://pmprb‐cepmb.gc.ca/home	Independent process. Potential overlap between drugs reviewed by PMPRB and pCODR.